fexapotide triflutate
Recently Published Documents


TOTAL DOCUMENTS

6
(FIVE YEARS 0)

H-INDEX

1
(FIVE YEARS 0)

2020 ◽  
Vol 38 (12) ◽  
pp. 3101-3111
Author(s):  
Neal Shore ◽  
Steven A. Kaplan ◽  
Ronald Tutrone ◽  
Richard Levin ◽  
James Bailen ◽  
...  

Abstract Purpose This study was undertaken to determine the safety and efficacy of fexapotide triflutate (FT) 2.5 mg and 15 mg for the treatment of Grade Group 1 prostate cancer. Methods Prospective randomized transrectal intraprostatic single injection FT 2.5 mg (n = 49), FT 15 mg (n = 48) and control active surveillance (AS) (n = 49) groups were compared in 146 patients at 28 U.S. sites, with elective AS crossover (n = 18) to FT after first follow-up biopsy at 45 days. Patients were followed for 5 years including biopsies (baseline, 45 days, and 18, 36, and 54 months thereafter), and urological evaluations with PSA every 6 months. Patients with Gleason grade increase or who elected surgical or radiotherapeutic intervention exited the study and were cumulatively included in the data analysis. Percentage of normal biopsies in baseline focus quadrant, tumor grades, and volumes; and outcomes including Gleason grade in entire prostate as well as treated prostate lobe, interventions associated with Gleason grade increase and total incidence of interventions were assessed. Results Significantly improved long-term clinical outcomes were found after 4-year follow-up, with percentages of patients progressing to interventions with and without Gleason grade increase significantly reduced by FT single treatment. Results in the FT 15-mg group were superior to the FT 2.5-mg dose group. There were no drug-related serious adverse events (SAEs). Conclusions FT showed statistically significant long-term efficacy in the treatment of Grade Group 1 patients regarding clinical and pathological progression. FT 15 mg showed superior results to FT 2.5 mg. There were no drug-related SAEs; FT injection was well tolerated.


2019 ◽  
Vol Volume 11 ◽  
pp. 343-350
Author(s):  
Paul Averback ◽  
Rajna Gohal ◽  
Marta Fuska ◽  
Kathleen Prins ◽  
Ping Wang

2019 ◽  
Vol 11 ◽  
pp. 175628721882080 ◽  
Author(s):  
Neal Shore ◽  
Ronald Tutrone ◽  
Claus G. Roehrborn

Male lower urinary tract symptoms (LUTS) is an increasingly important problem for the majority of late middle aged and elderly men. Fexapotide triflutate (FT) is a first in-class compound given by local injection via the transrectal intraprostatic route under ultrasound guidance. Data from >1700 FT and control injections in prospective randomized blinded controlled multicenter trials are reviewed and discussed in relation to current developments in the field of treatments for LUTS associated with benign prostatic hyperplasia (BPH). Long-term studies of FT in the United States have shown statistically significant improvement in BPH symptoms and objective outcomes including significant reduction in both spontaneous acute urinary retention as well as the subsequent incidence of BPH surgery. FT has been shown to be well tolerated with an excellent safety profile, and is an efficacious clinic-based treatment for BPH involving an intraprostatic injection that requires only a few minutes to administer, with no catheter nor anesthesia requirements.


2018 ◽  
Vol 36 (5) ◽  
pp. 801-809 ◽  
Author(s):  
Neal Shore ◽  
Ronald Tutrone ◽  
Mitchell Efros ◽  
Mohamed Bidair ◽  
Barton Wachs ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document